Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals (NQ: SYRS )

1.940 +0.010 (+0.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 155,900
Open 1.940
Bid (Size) 1.900 (10)
Ask (Size) 2.000 (2)
Prev. Close 1.930
Today's Range 1.890 - 2.030
52wk Range 1.430 - 8.170
Shares Outstanding 20,595,503
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire

Performance

YTD
-75.26%
-75.26%
1 Month
+25.16%
+25.16%
3 Month
-61.43%
-61.43%
6 Month
-59.75%
-59.75%
1 Year
-35.12%
-35.12%

More News

Read More
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
From Syros Pharmaceuticals
Via Business Wire
SYRS Investors Have Opportunity to Join Syros Pharmaceuticals, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Crude Oil Down 2%; Paysafe Shares Surge After Q2 Results
Via Benzinga
Exposures Fossil Fuels
S&P 500 Gains 1%; Home Depot Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
Via Benzinga
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
Via Benzinga
Why Is Syros Pharmaceuticals (SYRS) Stock Down 62% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Why Rumble Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
From Syros Pharmaceuticals
Via Business Wire
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
From Syros Pharmaceuticals
Via Business Wire
SYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024
Via InvestorPlace
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Participate in Upcoming Investor Conferences
From Syros Pharmaceuticals
Via Business Wire
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
From Syros Pharmaceuticals
Via Business Wire
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
From Syros Pharmaceuticals
Via Business Wire
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Top 3 Health Care Stocks You'll Regret Missing This Month
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.